NAFDAC Orders Nationwide Mop-Up of All EuroPharm Laboratories Products Over Quality, Safety Concerns
The National Agency for Food and Drug Administration and Control (NAFDAC) has announced a nationwide mop-up of all products manufactured and distributed by EuroPharm Laboratories, following findings that the company has been producing and distributing regulated medicines without the mandatory marketing authorisation (MA).
In a public alert issued on its verified X handle on Friday, NAFDAC said the enforcement action was triggered by credible intelligence and regulatory surveillance, which revealed that EuroPharm Laboratories had been manufacturing multiple pharmaceutical products in violation of its regulations.
According to the agency, several products discovered at the company’s facility failed to meet basic quality standards. Laboratory analysis conducted on selected samples confirmed “significant quality failures,” raising serious public health concerns.
Most alarming, NAFDAC said, were two batches of Linmoxyn (Amoxicillin) suspension which showed extremely low active pharmaceutical ingredient (API) content—13.9% and 18.4% instead of the acceptable level. Linmoxyn Amoxicillin 500mg capsules also failed analysis with an API content of only 48.3%, rendering the medicine grossly substandard and potentially dangerous to users.
The investigation uncovered several products bearing various NAFDAC Registration Numbers (NRNs) but allegedly produced and distributed without authorisation. The affected products include:
Linocloxin (Ampicillin & Cloxacillin) powder for suspension 100ml – NRN 04-4576
Linromycine (Erythromycin) powder for suspension 100ml – NRN 04-4573
Linocillin (Ampicillin) powder for suspension 50ml – NRN 04-4560
Linmoxyn (Amoxicillin 125mg) suspension 60ml – NRN 04-4567
Eurogyl (Metronidazole suspension) 50ml – NRN 04-4568
Naflin (Cough Expectorant) 100ml – NRN 04-4558
Natacid (Magnesium Trisilicate suspension) 100ml – NRN 04-5752
Navit-B Syrup (Vitamin B Complex) 100ml – NRN 04-4572
Fountain B-12 (Blood Tonic) 100ml – NRN 04-4569
Fountain B-12 (Blood Tonic) 200ml – NRN 04-4569
Vitamin-C Syrup 100ml – NRN 04-5001
Eurogyl (Metronidazole) Tablets 10×10 – NRN 04-4563
Eurogyl (Metronidazole) Tablets x1000 – NRN 04-4563
Euramol (Paracetamol) x1000 tablets – NRN 04-4564
Euramox (Mebendazole 100mg) tablets – NRN 04-4566
Linotrim (Cotrimoxazole suspension) 50ml – NRN 04-4574
Linoquine (Chloroquine Phosphate syrup 80mg/5ml) 60ml – NRN 04-4571
All products were traced to Europharm Laboratories, Eurolink Nigeria Limited, located at Anglo Jos New Industrial Area, Zarmaganda, Jos.
NAFDAC has urged distributors, retailers, pharmacists, healthcare workers and caregivers to exercise extreme caution across the supply chain to prevent further circulation of the substandard medicines.
The agency stressed that all medical products must be sourced only from authorised and licensed suppliers, and that consumers should carefully inspect products for authenticity and physical integrity.
Patients, caregivers and health professionals have also been advised to immediately report suspected cases of falsified or substandard medicines to the nearest NAFDAC office, via its toll-free number 0800-162-3322, or through email.
NAFDAC assured the public that it remains committed to safeguarding the health of Nigerians and will continue to intensify regulatory enforcement to protect the nation’s pharmaceutical space from harmful products.
